Skip to main content
. 2020 Jan 16;16(5):827–837. doi: 10.7150/ijbs.32460

Figure 2.

Figure 2

Effect of miR-9 plus cisplatin on HCC cell proliferation and apoptosis combined in vitro. (A-E) CCK-8 assay of the viability of HCC cells treated with miR-9 mimic, miR-9 inhibitor, or corresponding control RNAs in the presence of cisplatin (0, 1.5, 3.0, 4.5 μg/ml). (F-J) EdU assay of cell proliferation rate under cisplatin in HCC cell lines treated with miR-9 mimic, miR-9 inhibitor, or control RNAs. The EdU-positive cells were counted. *vs. cisplatin, #vs. cisplatin plus miR-9 mimic, *P < 0.05, **P < 0.01, ***P < 0.001, ##P < 0.01, ###P < 0.001.(K).QRT-PCR of miR-9 level in HCC cell treated with miR-9 mimic , inhibitor or combined with cisplatin, *P<0.05.